
Organic Process Research and Development p. 387 - 398 (2017)
Update date:2022-09-26
Topics:
Linghu, Xin
Wong, Nicholas
Iding, Hans
Jost, Vera
Zhang, Haiming
Koenig, Stefan G.
Sowell, C. Gregory
Gosselin, Francis
The process development of a synthetic route to manufacture ERK inhibitor GDC-0994 on multikilogram scale is reported herein. The API was prepared as the corresponding benzenesulfonate salt in 7 steps and 41% overall yield. The synthetic route features a biocatalytic asymmetric ketone reduction, a regioselective pyridone SN2 reaction, and a safe and scalable tungstate-catalyzed sulfide oxidation. The end-game process involves a telescoped SNAr/desilylation/benzenesulfonate salt formation sequence. Finally, the development of the API crystallization allowed purging of process-related impurities, obtaining >99.5A% HPLC and >99% ee of the target molecule.
Hangzhou Share Chemical Co., Ltd(expird)
Contact:+86-57187093700
Address:Hang Xing Road
PharmaResources(Kaiyuan)CO,.Ltd
Contact:+86-21-50720028
Address:No.3, Beihuan Road, Economic Development District, Kaiyuan City, Tieling City, Liaoning Province, China 112300
Contact:+86-371-55981030
Address:Room 1571, Macalline Soho, No.1, Shangdu Road, Zhengzhou, Henan
Hubei Onward Bio-Development Co., Ltd.
Contact:+86-718-8417012
Address:No.517,Shizhou Avenue,Enshi City,Hubei Province,China,445002
Contact:+86 021-51698675
Address:1701, Jielong Plaza, No.618 Pingliang Rd, ShangHai,China
Doi:10.1002/adsc.201300419
(2013)Doi:10.1016/j.cplett.2013.08.029
(2013)Doi:10.1002/chem.201300817
(2013)Doi:10.1021/jacs.0c07381
(2020)Doi:10.1021/ja00978a026
(1967)Doi:10.1016/0040-4039(93)89012-F
(1993)